Targeting intratumoral bacteria reverses MHC-I suppression and enhances nano-based chemoimmunotherapy in colorectal cancer
Open Access
- 7 May 2026
- journal article
- Published by Elsevier in Military Medical Research
- Vol. 13 (1)
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2021-I2M-1-026)
This publication has 30 references indexed in Scilit:
- Metal/metal oxide nanoparticles with antibacterial activity and their potential to disrupt bacterial biofilms: Recent advances with emphasis on the underlying mechanismsAdvances in Colloid and Interface Science, 2025
- Emerging mechanistic insights into liposomal stability: Full process management from production and storage to food applicationChemical Engineering Journal, 2025
- IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasionCell, 2024
- Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast CancerACS Nano, 2024
- Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2023
- Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatmentCell, 2023
- Emerging roles of intratumor microbiota in cancer metastasisTrends in Cell Biology, 2022
- Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancerCell, 2022
- Hyaluronic acid and albumin based nanoparticles for drug deliveryJournal of Controlled Release, 2021
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulatorsNature, 2017